Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Novel strategies have been developed to reduce or avoid intravitreal injections (IVTs) of the antiangiogenic (ranibizumab (RBZ)) and anti-inflammatory (triamcinolone acetonide (TA)) agents used to treat vitreoretinal diseases. One of the strategies includes liposomes. This study evaluated the safety...

Full description

Bibliographic Details
Main Authors: Jose Navarro-Partida, Juan Carlos Altamirano-Vallejo, Luis Abraham Aceves Franco, Jesús Gonzalez-Cortes, Sergio Hernandez-Da Mota, Jose Gerardo García-Aguirre, Carlos David Azuara-Galindo, Carlos Rodrigo Castro-Castaneda, Juan Armendariz-Borunda, Arturo Santos
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceutics
Subjects:
triamcinolone acetonide
liposomes
neovascular age-related macular degeneration
wet macular degeneration
adjuvant therapy
ranibizumab
Online Access:https://www.mdpi.com/1999-4923/13/9/1491

Internet

https://www.mdpi.com/1999-4923/13/9/1491

Similar Items